Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer

PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients. Several of those patients exhibit intrinsic/acquired resistance mechanisms that limit efficacy of PARPi monotherapy. Here we show how the efficacy of PARPi in triple-negative breast cancers (TNBC) can be expanded by targeting...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Principais autores: Carey, Jason. P.W., Karakas, Cansu, Bui, Tuyen, Chen, Xian, Vijayaraghavan, Smruthi, Zhao, Yang, Wang, Jing, Mikule, Keith, Litton, Jennifer K., Hunt, Kelly K., Keyomarsi, Khandan
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5811386/
https://ncbi.nlm.nih.gov/pubmed/29180466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-1494
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados